Skip to content

AVADEL PHARMACEUTICALS PLC

CIK 0001012477

← back to feed
Revenue (TTM)
$248.13M
+504.8% YoY Q3 Oct 2025
Net Income (TTM)
$2.14M
+69.5% YoY Q3 Oct 2025
EPS Diluted (TTM)
$0.02
+74.5% YoY Q3 Oct 2025
Gross Margin
94.4%
Q3 Oct 2025
Operating Margin
3.0%
Q3 Oct 2025
Net Margin
0.9%
Q3 Oct 2025
Free Cash Flow (TTM)
−$102.27M
Q3 Oct 2025
Cash
$79.81M
Q3 Oct 2025
Total Debt
$679K
Q3 Oct 2025
Shares Outstanding
97.66M sh
Q3 Oct 2025

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings